Zhu 2013b.
Methods | Study design: Randomised clinical trial Study duration: March 2008 to June 2009 Duration of follow‐up: 3 years Setting: Hospital |
Participants | Age (mean ± SD, range): TACE + MWA: 53.6 years, 27‐80 years; TACE alone: 51.2 years, 28‐79 years Male (n/total): TACE + MWA: 12/18; TACE alone: 11/18 |
Interventions | TACE + MWA group (n = 18): TACE: TACE comprised of hepatic arterial infusion chemotherapy and hepatic artery embolisation A total of 2‐4 sessions of TACE were performed, with an interval of 3‐4 weeks. MWA: Output power of 50‐80 W, 4‐10 minutes per ablation session TACE group (n = 18): TACE comprised of hepatic arterial infusion chemotherapy and hepatic artery embolisation. A total of 2‐4 episodes of TACE were performed, with an interval of 3‐4 weeks. |
Outcomes | Serum level of AFP 1‐, 2‐, and 3‐year survival rates |
Notes | Country of study: China
Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this. |